Daniel Ginard
Overview
Explore the profile of Daniel Ginard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ginard D, Fontanillas N, Baston-Rey I, Pejenaute M, Piqueras M, Alcalde S, et al.
Gastroenterol Hepatol
. 2025 Feb;
48(3):502255.
PMID: 39986803
Primary Care is the first point of contact for most patients after the onset of symptoms of inflammatory bowel disease (IBD). Establishing an initial diagnostic process based on compatible symptoms...
2.
Ginard D, Fontanillas N, Baston-Rey I, Pejenaute M, Piqueras M, Alcalde S, et al.
Semergen
. 2025 Jan;
102334.
PMID: 39833019
Primary Care is the first point of contact for most patients after the onset of symptoms of inflammatory bowel disease (IBD). Establishing an initial diagnostic process based on compatible symptoms...
3.
Giordano A, Perez-Martinez I, Gisbert J, Ricart E, Martin-Arranz M, Mesonero F, et al.
Am J Gastroenterol
. 2025 Jan;
120(1):194-203.
PMID: 39745305
Introduction: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between...
4.
Marras C, Labarga M, Ginard D, Carrascosa J, Escudero-Contreras A, Collantes-Estevez E, et al.
JMIR Form Res
. 2024 Dec;
8:e56553.
PMID: 39622680
Background: Switching to biosimilars is an effective and safe practice in treating inflammatory diseases; however, a nocebo effect may arise as a result of the way in which the switch...
5.
Ricart E, Bastida G, Carpio D, Ceballos D, Ginard D, Marin-Jimenez I, et al.
Crohns Colitis 360
. 2024 Oct;
6(4):otae055.
PMID: 39445340
Background: We aimed to (1) analyze the applicability of the updated Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations in real-world clinical practice, (2) identify barriers to their implementation,...
6.
Ginard D, Barreiro-de Acosta M, Nos P, Moraleja I, Munoz Nunez F, Aldeguer X, et al.
Dig Dis
. 2024 Aug;
42(6):600-609.
PMID: 39173598
Introduction: Identifying novel treatment strategies for patients with ulcerative colitis (UC) and at risk of relapse is critical. The objective of this study was to assess the efficacy of beclomethasone...
7.
Maimo-Barcelo A, Martin-Saiz L, Barcelo-Nicolau M, Salivo S, Perez-Romero K, Rodriguez R, et al.
Biochim Biophys Acta Mol Cell Biol Lipids
. 2024 Jun;
1869(7):159528.
PMID: 38936507
Inflammatory Bowel Disease (IBD) comprises a heterogeneous group of chronic inflammatory conditions of the gastrointestinal tract that include ulcerative colitis (UC) and Crohn's disease. Although the etiology is not well...
8.
Rodriguez-Lago I, Herrera-deGuise C, Bosca-Watts M, Rodriguez C, Leo-Carnerero E, Calvo Iniguez M, et al.
Gastroenterol Hepatol
. 2024 May;
47(10):502195.
PMID: 38710466
Objective: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in ulcerative colitis (UC), also in combination with biologics, mainly with anti-TNF. The aim of this study was to...
9.
Gonzalez-Lama Y, Ricart E, Carpio D, Bastida G, Ceballos D, Ginard D, et al.
BMJ Open Gastroenterol
. 2024 Jan;
11(1).
PMID: 38267072
Background: Despite research, there are still controversial areas in the management of Crohn's disease (CD). Objective: To establish practical recommendations on using anti-tumour necrosis factor (TNF) drugs in patients with...
10.
Rodriguez-Lago I, Canete F, Guerra-Del-Rio E, Herrera-deGuise C, Iglesias E, Leo E, et al.
Gastroenterol Hepatol
. 2024 Jan;
47(7):727-733.
PMID: 38266817
Objective: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in treating ulcerative colitis (UC), also in combination with biologics. The objective of this study is to evaluate the...